Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on prostate cancer.

B I Rini1, E J Small

  • 1University of Chicago Medical Center, Chicago, Illinois 60637-1470, USA. brini@medicine.bsd.uchicago.edu

Current Opinion in Oncology
|April 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.

ESMO open·2023
Same author

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

The number of positive prostate biopsy samples can improve cancer outcome prediction after surgery. Research also explores advanced treatments for localized and metastatic prostate cancer, focusing on quality of life.

Area of Science:

  • Oncology
  • Urology
  • Cancer Research

Background:

  • Prostate cancer management involves various factors like T stage, Gleason score, and PSA levels.
  • Treatment strategies are evolving for localized and metastatic prostate cancer.
  • Quality of life is a critical consideration in prostate cancer research.

Purpose of the Study:

  • To evaluate the prognostic value of positive prostate biopsy sample count.
  • To review current and emerging treatments for prostate cancer.
  • To highlight the importance of quality of life in prostate cancer research.

Main Methods:

  • Analysis of prostate biopsy data for cancer prediction.
  • Review of treatment modalities including radiation, brachytherapy, and hormone therapy.

Related Experiment Videos

  • Assessment of quality of life metrics in prostate cancer patients.

    • Main Results:

    • The number of positive biopsy samples provides additional predictive information for radical prostatectomy outcomes.
    • Higher radiation doses and neoadjuvant hormone therapy show success in high-risk patients.
    • Brachytherapy is an established option for localized prostate cancer, with ongoing definition of outcomes and toxicity.

    Conclusions:

    • Integrating positive biopsy sample counts enhances prostate cancer outcome prediction post-surgery.
    • Advanced therapies are being developed for various stages of prostate cancer.
    • Quality of life assessment is integral to comprehensive prostate cancer care.